Clinical Trials Logo

Progressive Keratoconus clinical trials

View clinical trials related to Progressive Keratoconus.

Filter by:

NCT ID: NCT06450470 Not yet recruiting - Clinical trials for Progressive Keratoconus

Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus

Start date: July 2024
Phase: Phase 3
Study type: Interventional

Crosslinking is a therapeutic technique used to increase the rigidity of the cornea in order to slow or stop progression of keratoconus. The main complication of the treatment of keratoconus by crosslinking is postoperative pain due to the removal of the corneal epithelium. Currently, the management of pain is done through the administration of artificial tears and paracetamol. The amniotic membrane is a biological tissue used in ophthalmology to treat injuries of the surface of the eye. It has healing and analgesic properties. The objective of this multicenter randomized study is to evaluate the benefit of placing an amniotic membrane on the eye post-crosslinking to reduce pain and promote corneal healing.

NCT ID: NCT05314738 Recruiting - Clinical trials for Progressive Keratoconus

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

Start date: March 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.

NCT ID: NCT04504578 Completed - Clinical trials for Progressive Keratoconus

Efficacy and Safety ofCACXL in the Treatment of Keratoconus With Thin Corneas

CACXL
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to detect the safety and effectiveness of contact lens assisted corneal cross linking in managing progressive keratoconus with thin corneas CACXL was done for 40 eyes of 30 of keratoconic patients presented to cornea outpatient clinic in Kasr Alainy teaching hospital The UDVA ,BDVA KMAX, thinnest corneal thickness pre-operative and 9 months postoperatively and the endothelial cell count was measured preoperative and 3 months postoperative Demarcation line was measured after 1 month by using ASOCT There was statistical significant difference in UDVA and BDVA, there was stabilization of Kmax there was decrease in endothelial cell count but not statistically significant According to results the procedure seems to be effective and safe un managing progressive keratoconus.

NCT ID: NCT04427956 Active, not recruiting - Clinical trials for Progressive Keratoconus

Corneal Crosslinking Treatment Study

Start date: May 23, 2017
Phase: Phase 4
Study type: Interventional

Three different protocols for inducing corneal crosslinks in subjets with progressive keratoconus will be evaluated in this randomised clinical study.

NCT ID: NCT04045626 Recruiting - Clinical trials for Progressive Keratoconus

Study of Demarcation Line Depth in Transepithelial Versus Epithelium-off Accelerated Cross-linking (AXL) in Keratocouns

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

To assess depth of demarcation line in transepithelial versus epithelium-off accelerated cross-linking in keratoconus patients

NCT ID: NCT03442751 Completed - Clinical trials for Progressive Keratoconus

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

Start date: April 6, 2018
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus. Epithelium-on CXL uses a formulation that allows the riboflavin to penetrate the cornea without the need to remove the epithelium, the outer most layer of the cornea.

NCT ID: NCT02883868 Completed - Clinical trials for Progressive Keratoconus

Stromal Demarcation Line: is it Predictive for Cross-Linking Efficiency?

STROMA-CROSS
Start date: October 2015
Phase: N/A
Study type: Observational

To assess the association between stromal demarcation line after collagen crosslinking (CXL) for progressive keratoconus and mid-term (6 month) refractive, topographic and clinical outcomes of CXL

NCT ID: NCT02721628 Recruiting - Clinical trials for Progressive Keratoconus

Epi-keratoplasty Versus Collagen Cross-Linking in Progressive Keratoconus

Start date: September 2015
Phase: N/A
Study type: Interventional

Epi-keratoplasty Versus Collagen Cross-Linking in Progressive Keratoconus

NCT ID: NCT02117999 Completed - Clinical trials for Progressive Keratoconus

Transepithelial Corneal Cross-linking Using Iontophoresis

T-iontoCL
Start date: January 2014
Phase: N/A
Study type: Interventional

The purpose of the present Randomized Clinical Trial (RCT) is to compare the efficacy and safety of transepithelial corneal cross-linking using iontophoresis (T-ionto CL) to treat progressive keratoconus in comparison with standard cross-linking (standard CL).

NCT ID: NCT01868620 Terminated - Clinical trials for Progressive Keratoconus

Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.

IONTO-CXL
Start date: May 2013
Phase: N/A
Study type: Interventional

The primary purpose of the protocol is to compare the current standard CXL with iontophoretic CXL to provide evidence in relation to the efficacy and safety in progressive keratoconus. Corneal collagen crosslinking (CXL) is the first surgical procedure that appears to halt the progression of keratoconus. In the current standard CXL, the central corneal epithelium must be debrided to efficiently permeate the corneal stroma with riboflavin. The epithelium debridement can cause severe pain, infection and stromal haze. The study hypothesis is that iontophorese CXL is as effective as standard CXL to stabilize a progressive keratoconus.